摘要
医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)是我国现患率居第一位的医院感染性疾病。国内外相关指南相继进行了更新,旨在提高HAP/VAP诊断和治疗水平,改善患者的结局,但我们仍然面临诸多挑战。降钙素原(PCT)是较C反应蛋白(CRP)更特异的感染相关生物学标志物,对重症细菌感染和脓毒症具有反应快速、特异性高的优点,动态监测PCT可指导HAP/VAP的诊断及抗菌药物治疗的疗程。
Hospital-acquired pneumonia(HAP)and ventilator-associated pneumonia(VAP)rank first among prevalence rates of nosocomial infections in China.Although the guidelines of HAP/VAP have been updated in China and at abroad recently,there are still some challenges to improve the skills of diagnosis and treatment of HAP/VAP,and ultimately to improve the outcomes.Procalcitonin(PCT),a more specific biomarker of infection than C-reactive protein(CRP),is elevated rapidly in severe bacterial infection and sepsis.Dynamic monitoring of PCT can be used to guide the diagnosis of HAP/VAP and the course of antimicrobial treatment.
作者
占扬清
叶枫
ZHAN Yang-qing;YE Feng(Department of Pulmonary and Critical Care Medicine,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,State Key Laboratory of Respiratory Disease,National Clinical Research Centre for Respiratory Disease,Guangdong 510120,China)
出处
《中国临床新医学》
2020年第1期16-20,共5页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
国家科技重大专项课题(编号:2017ZX09304005002)
关键词
医院获得性肺炎
呼吸机相关性肺炎
降钙素原
抗菌药物
Hospital-acquired pneumonia(HAP)
Ventilator-associated pneumonia(VAP)
Procalcitonin(PCT)
Antibacterial agents
